Figure 7. Increased skeletal muscle fatty acid oxidation is supported by AMPK‐mediated suppression of lipogenesis in white adipose tissue following treatment with BAM15.

• A–D
  (A) Plasma concentrations of non‐esterified fatty acids (NEFAs) (CTRL N = 7, BAM15 N = 8, P = 0.0073), (B) leptin (N = 8 per group, P < 0.0001), (C) GDF15 (N = 7 per group, P = 0.035), and (D) FGF21 (N = 7 per group, P = 0.0026) after 3 weeks of CTRL or BAM15 treatment.
• E, F
  (E) Total (basal: P = 0.015) and (F) complete (basal: P = 0.0137) oxidation of 200 μM [1‐¹⁴C]palmitate to CO₂ from mixed gastrocnemius muscle homogenates (N = 7 per group).
• G
  Routine (R) oxygen flux, leak (L), OXPHOS (P), and ETC. (E) capacity in permeabilized mixed gastrocnemius fibers (N = 6 per group). PM: pyruvate and malate, ADP: adenosine diphosphate, GS: glutamate and succinate, Tm: tetramethyl‐p‐phenylenediamine, PalM: palmitoylcarnitine and malate, Oct: octanoylcarnitine, and Dur: duroquinol.
• H–K
  (H) Representative immunoblots of phosphorylated and total AMPK and ACC from iWAT, and mixed gastrocnemius muscle and (I‐K) densitometric quantification (N = 4 per group; iWAT p‐AMPK^T172: P = 0.0186, iWAT p‐ACC^S79: P = 0.0083, mixed gastrocnemius p‐AMPK^T172: P = 0.0286).
• L–N
  mRNA expression of transcriptional regulators of lipogenesis and lipolysis in iWAT (N = 7 per group). Srebf1 (P < 0.0001), Mlxipl (P = 0.0018), Scd1 (P < 0.0001), FASN (P = 0.0009), LIPE (P = 0.0015), Pnpla2 (P < 0.0001), PPARg (P < 0.0001).

Data information: Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Panels E, F, and G were assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panels A, B, C, D, I, J, K, L, M, and N were assessed by an unpaired Student's t‐test. Source data are available online for this figure.